Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Photoimmunotherapy
HSMN NewsFeed - 23 Dec 2020
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals
Oncology
HSMN NewsFeed - 25 Sep 2020
Rakuten Medical Japan Announces Marketing Approval of Akalux(R) IV Infusion 250mg and BioBlade(R) Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
Biopharmaceuticals
Oncology
Regulatory
HSMN NewsFeed - 31 May 2019
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence
Biopharmaceuticals
Oncology
HSMN NewsFeed - 1 Mar 2019
Rakuten Aspyrian Announces Name Change to Rakuten Medical
Biopharmaceuticals
Oncology
HSMN NewsFeed - 23 Aug 2018
Rakuten Aspyrian Raises $150 Million in Series C Financing
Biopharmaceuticals
Oncology
Venture Capital
HSMN NewsFeed - 12 May 2015
Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer
Biopharmaceuticals
Oncology
FDA
Return to NewsFeed